Skip to main content
APGE
NASDAQ Life Sciences

Apogee Therapeutics Reports $1.3B Cash, Extends Runway to 2029, Advances Lead Drug to Phase 3

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$82.95
Mkt Cap
$6.255B
52W Low
$34.34
52W High
$95.315
52W Position info
142% above low
Off High info
13% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

APGE has more than doubled off its 52-week low of $34.34.

Summary

Apogee Therapeutics announced strong Q1 2026 financial results, boasting $1.3 billion in cash and an extended runway into 2029, alongside positive clinical progress for its lead drug, zumilokibart.


Key Events · Product Development and Regulatory · APGE

  • Strong Cash Position

    Cash, cash equivalents, and marketable securities reached $1.3 billion as of March 31, 2026, a significant increase from $902.9 million at year-end 2025, following a $403 million public equity offering.

  • Extended Cash Runway

    The company now expects its existing capital to fund operations into 2029, providing a long runway through a planned Biologics License Application (BLA) filing for zumilokibart in atopic dermatitis.

  • Zumilokibart Advances to Phase 3

    Positive 52-week Phase 2 Part A data for zumilokibart in moderate-to-severe atopic dermatitis demonstrated durable maintenance and improved efficacy. Phase 3 trials are expected to initiate in the second half of 2026.

  • Pipeline Expansion Plans

    Plans are underway to expand zumilokibart into asthma and eosinophilic esophagitis (EoE) trials, with further details expected later this year.


Analysis · APGE · Life Sciences

This 8-K provides a strong financial and clinical update. The company's cash position has significantly increased to $1.3 billion, extending its operational runway into 2029. This substantial funding de-risks the company's ability to advance its pipeline, particularly zumilokibart, which showed durable efficacy in Phase 2 atopic dermatitis data and is slated for Phase 3 initiation later this year. The extended runway provides critical stability for a clinical-stage biotech.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, APGE was trading at $82.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $34.34 to $95.32. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

APGE - Latest Insights

APGE
Sep 03, 2026, 8:53 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $135.11
Real-time Price: $135.11 info
Change: $0 (0%) info
Market Cap: $10.223B info
APGE
Aug 11, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $134.69
Real-time Price: $135.11 info
Change: +$0.420 (+0.31%) info
Market Cap: $10.223B info
APGE
Aug 10, 2026, 7:52 AM EDT
Filing Type: 10-Q
Importance Score:
10
Price at Filing: $134.62
Real-time Price: $135.11 info
Change: +$0.486 (+0.36%) info
Market Cap: $10.223B info
APGE
Aug 10, 2026, 7:19 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $134.79
Real-time Price: $135.11 info
Change: +$0.320 (+0.24%) info
Market Cap: $10.223B info
APGE
Aug 06, 2026, 6:31 AM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $134.27
Real-time Price: $135.11 info
Change: +$0.840 (+0.63%) info
Market Cap: $10.223B info